Category
23 articles
Walmart, Amazon, and Zipline are scaling drone delivery into American suburbs, and they're doing it before anyone decided who the air above your house belongs to. The regulatory vacuum isn't an accident — it's the business model.
America's electrical grid was built for a world that no longer exists — and the weather is making sure we know it. A wave of AI and hardware startups is racing to teach a century-old system to heal itself before the next Texas-style blackout.
The science of living longer is advancing faster than most people realize — but the treatments are landing almost exclusively in the hands of the ultra-wealthy. From senolytic therapies to experimental plasma clinics, a biological class divide is quietly forming, and its consequences could be more disruptive than anything technology has produced before.
A small but growing cluster of physicists, philosophers, and venture capitalists are putting serious money and serious careers behind one of the most destabilizing ideas in science: that the universe isn't just *like* a computer — it literally is one. Here's what the actual research looks like, why Silicon Valley is paying attention, and what happens to everything we think we know if they turn out to be right.
AI chatbots have quietly become the go-to source for understanding tomorrow's technology landscape — but there's a growing problem nobody wants to talk about. These systems are confidently fabricating breakthroughs, trends, and timelines that don't exist yet, and the ripple effects are already warping how investors, founders, and the public think about what's actually coming. The most dangerous predictions about the future might be the ones a machine just made up.
Tech giants, pharma conglomerates, and well-funded sleep startups are quietly filing patents on everything from your dream patterns to personalized sleep interventions. The battlefield isn't a boardroom — it's your bedroom. And by the time most people notice, the intellectual property surrounding human sleep may already be locked up.
Brain-computer interfaces are inching out of research labs and into everyday life — and advertisers are already circling. The next frontier of targeted marketing isn't your phone screen. It might be your neurons.
While you're grabbing coffee or sitting in traffic, your precise location is being auctioned off to hedge funds, retailers, and political operatives — often dozens of times per minute. The data broker industry has quietly built a surveillance infrastructure so granular it can predict your behavior before you act on it. Here's how it works, who's profiting, and why it's almost entirely legal.
Quantum computing is no longer a science fair experiment — it's closing in on the moment when every encrypted secret on the internet becomes readable. The race between quantum attackers and quantum defenders is already underway, and most Americans have no idea it's happening.
A handful of well-funded startups are promising to resurrect woolly mammoths, passenger pigeons, and Tasmanian tigers using cutting-edge gene editing. But behind the splashy headlines and venture capital checks, the science, ethics, and economics of de-extinction are far messier than the pitch decks suggest.
A new wave of neurotechnology companies is building tools that can read consumer intent before it reaches conscious thought — and the advertising industry is paying close attention. The regulatory framework to stop them barely exists. Here's what's actually at stake.
A wave of synthetic biology startups is engineering microbes and cells to manufacture everything from spider silk to cancer drugs — no mines, no oil wells, no traditional supply chains required. If it works, the economic implications could be staggering. If it doesn't, we'll have spent a decade learning exactly how complicated life really is.
Genetic sequencing is cheaper than ever, and a booming shadow market has emerged around your most intimate data — your DNA. From insurance actuaries to foreign intelligence agencies, the buyers are lining up, and most Americans have no clue their biological blueprint is already in play.
A new wave of neurotechnology companies is chasing one of the most audacious goals in the history of medicine: turning your memories into data you can keep forever. Billions in venture capital are flowing in, the science is getting real, and the ethical questions are getting louder. Here's what's actually happening inside the memory market.
A new wave of neurotechnology startups is chasing one of humanity's oldest obsessions — cheating death — by attempting to map, digitize, and preserve the human brain. Billionaires are quietly writing enormous checks, scientists are deeply divided, and the ethical questions are only getting louder.
The biotech industry is producing breakthrough after breakthrough, but a quiet infrastructure crisis is threatening to stall the whole party. From specialized reagents to fermentation tanks, the unglamorous plumbing of biomanufacturing can't keep up — and the companies solving that problem might end up being the biggest winners of the decade.
Protein structure prediction was a fifty-year scientific puzzle. AI cracked it in a weekend — and now everyone from Google to scrappy biotech startups is fighting to control what comes next. The technology underpinning this gold rush could reshape medicine, agriculture, and materials science, but the geopolitical and ethical stakes of who wins may be even bigger than the science itself.
A wave of well-funded startups has spotted something in America's loneliness epidemic — a market. From AI companions to algorithmically curated social clubs, these companies are betting that disconnection is the next great consumer problem to solve. But when profit enters the picture, it's worth asking whether these platforms are building bridges or just selling you a prettier version of the wall.
AlphaFold cracked the code on how proteins fold — now a new generation of biotech startups is using that same logic to engineer entirely new foods from scratch. The race to feed a warming, overcrowded planet may have just found its most powerful weapon yet.
While Big Pharma chases blockbuster profits, a scrappy underground of biohackers and former lab researchers are tackling the diseases no corporation wants to touch. Working out of converted garages and community lab spaces, these DIY scientists are rewriting the rules of drug development — and forcing a real conversation about who gets to decide what medicine looks like.
Millions of Americans are logging off from human relationships and logging into AI chatbots for their daily dose of emotional support. But as the companion app industry explodes, mental health professionals are raising serious alarms about what happens when your most attentive listener was designed by an engagement algorithm.
AI systems are inching toward something that looks uncomfortably like reasoning — and our ethical frameworks are nowhere close to ready. Researchers are raising alarms, corporate guardrails are showing cracks, and the assumption that we can simply regulate our way out of this is starting to look dangerously naive.
While Silicon Valley stays hypnotized by large language models, a quieter revolution is being engineered one organism at a time in wet labs across the country. Synthetic biology is on the verge of producing the decade's most consequential breakthroughs — and venture capital is only just starting to wake up to it.